ACER - Acer Therapeutics Inc. Stock Price and Quote

ACER [NASD]

Index	-	P/E	-	EPS (ttm)	-1.44	Insider Own	19.50%	Shs Outstand	16.09M	Perf Week	1.13%
Market Cap	12.74M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	60.08%	Shs Float	13.36M	Perf Month	-63.00%
Income	-21.30M	PEG	-	EPS next Q	-0.37	Inst Own	26.10%	Short Float / Ratio	2.53% / 0.75	Perf Quarter	-70.83%
Sales	0.40M	P/S	31.86	EPS this Y	47.60%	Inst Trans	0.99%	Short Interest	0.34M	Perf Half Y	-45.82%
Book/sh	-0.76	P/B	-	EPS next Y	55.40%	ROA	-80.10%	Target Price	8.50	Perf Year	-73.84%
Cash/sh	0.38	P/C	1.99	EPS next 5Y	-	ROE	259.30%	52W Range	0.65 - 4.56	Perf YTD	-69.78%
Dividend	-	P/FCF	-	EPS past 5Y	38.00%	ROI	902.80%	52W High	-83.37%	Beta	0.72
Dividend %	-	Quick Ratio	0.40	Sales past 5Y	-15.40%	Gross Margin	-	52W Low	16.69%	ATR	0.14
Employees	35	Current Ratio	0.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	22.88	Volatility	7.72% 12.83%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-36.10%	Profit Margin	-	Rel Volume	0.35	Prev Close	0.75
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	452.59K	Price	0.76
Recom	2.00	SMA20	-39.13%	SMA50	-58.49%	SMA200	-55.37%	Volume	157,707	Change	1.13%

Jun-26-19

Reiterated

H.C. Wainwright

Buy

$55 → $10

Jun-25-19

Downgrade

William Blair

Outperform → Mkt Perform

Jun-25-19

Downgrade

Raymond James

Outperform → Mkt Perform

May-23-19

Initiated

Wedbush

Outperform

Feb-15-19

Resumed

Raymond James

Outperform

$40

Dec-20-18

Initiated

Needham

Buy

$48

Feb-26-18

Initiated

ROTH Capital

Buy

Dec-20-17

Initiated

H.C. Wainwright

Buy

$50

Mar-27-23 04:01PM	Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update GlobeNewswire
Mar-22-23 08:30AM	Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes GlobeNewswire -5.18%
08:00AM	Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire
Mar-20-23 12:01PM	ACER's Stock Down on Failure of Phase II Study, Cash Updates Zacks +26.87%
Mar-17-23 01:34PM	Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study Benzinga -56.77%
08:30AM	Loading…
08:30AM	Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial GlobeNewswire
Mar-15-23 08:30AM	Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA Program Update GlobeNewswire
Mar-10-23 05:50PM	Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should Know Zacks
Feb-23-23 05:50PM	Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-22-23 06:00PM	Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know Zacks
Feb-13-23 08:30AM	Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause GlobeNewswire
Feb-10-23 05:50PM	Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know Zacks
11:30AM	Acer (ACER) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-01-23 05:50PM	Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-31-23 08:00AM	SWK Holdings Provides Portfolio Update Highlighting Recent Achievements PR Newswire
07:05AM	Loading…
Jan-27-23 07:05AM	7 Micro-Cap Stocks to Buy for Risk-Taking Investors InvestorPlace
Jan-25-23 06:00PM	Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know Zacks
Jan-19-23 06:00PM	Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should Know Zacks
08:23AM	Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics Zacks
Jan-18-23 08:49AM	5 Stocks to Buy as the Drug Industry Bets Big on Innovation Zacks
Jan-16-23 09:40AM	Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year? Zacks
Jan-10-23 06:00PM	Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-09-23 08:30AM	Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones GlobeNewswire
Jan-05-23 08:30AM	Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate GlobeNewswire
Dec-29-22 09:40AM	Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year? Zacks
08:30AM	Acer Therapeutics Compliant with All Nasdaq Listing Criteria GlobeNewswire
Dec-28-22 12:00PM	Acer Therapeutics Inc. (ACER) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
10:39AM	12 Best Biotech Stocks to Buy Under $10 Insider Monkey
09:28AM	ACER Down Despite FDA Nod for Urea Cycle Disorders Drug Zacks
Dec-27-22 08:30AM	Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders GlobeNewswire -33.33%
02:47PM	Loading…
Dec-23-22 02:47PM	UPDATE 1-U.S. FDA approves Acer Therapeutics' genetic disorder drug Reuters -10.36%
Dec-13-22 09:40AM	Is Acer Therapeutics (ACER) Stock Outpacing Its Medical Peers This Year? Zacks +9.59%
Dec-08-22 09:35PM	2 Biotech Stocks Under $10 That Could Win From Key FDA Approvals TipRanks
Dec-04-22 07:17AM	Trade Alert: The Founder Of Acer Therapeutics Inc. (NASDAQ:ACER), Christopher Schelling, Has Just Spent US$1m Buying 43% More Shares Simply Wall St.
Nov-30-22 08:30AM	Acer Therapeutics Announces $1.5M Private Placement GlobeNewswire +9.48%
Nov-17-22 05:37AM	Acer Therapeutics Third Quarter 2022 Earnings: US$0.31 loss per share (vs US$0.23 loss in 3Q 2021) Simply Wall St.
Nov-14-22 05:08PM	Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate Update GlobeNewswire
Oct-26-22 08:30AM	Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO (celiprolol) GlobeNewswire
Oct-18-22 04:05PM	SWK Holdings Provides Portfolio Update Highlighting Recent Achievements PR Newswire
Oct-06-22 08:30AM	Acer Therapeutics Announces University of North Carolina Receives Department of Defense Grant to Support the Proposed Investigator Sponsored OASIS Trial of ACER-801 (Osanetant) to Reduce the Frequency and Severity of Post-Traumatic Stress Disorder GlobeNewswire
Oct-05-22 01:44PM	Acer Therapeutics Expands ACER-801 Development Into Post-Traumatic Stress Disorder Benzinga
08:30AM	Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress Disorder GlobeNewswire
Oct-03-22 08:30AM	Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate GlobeNewswire
Sep-30-22 11:47AM	Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA Zacks
Sep-29-22 11:42AM	KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study Zacks -9.09%
Sep-15-22 01:28PM	Altimmune's (ALT) Data From NASH Study Fail to Impress Investors Zacks
Sep-13-22 11:58AM	Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study Zacks -6.37%
Aug-23-22 08:30AM	Acer Therapeutics to Participate in August and September 2022 Investor Conferences GlobeNewswire
Aug-15-22 04:00PM	Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update GlobeNewswire
Aug-12-22 08:30AM	Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease GlobeNewswire
Jul-28-22 08:33AM	Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease GlobeNewswire
08:30AM	Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs GlobeNewswire
07:32AM	New Strong Sell Stocks for July 28th Zacks
Jul-18-22 08:30AM	Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs GlobeNewswire
Jul-15-22 06:15AM	New Strong Sell Stocks for July 15th Zacks +6.53%
Jul-08-22 08:30AM	Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form GlobeNewswire +8.57%
06:25AM	New Strong Sell Stocks for July 8th Zacks
Jun-28-22 06:16AM	New Strong Sell Stocks for June 28th Zacks
Jun-27-22 08:30AM	Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome GlobeNewswire +17.21%
Jun-23-22 08:14AM	New Strong Sell Stocks for June 23rd Zacks -9.16%
Jun-22-22 09:43AM	Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug Zacks -5.76%
Jun-21-22 01:12PM	FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate Benzinga -21.02%
08:32AM	Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer GlobeNewswire
08:30AM	Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001 GlobeNewswire
Jun-15-22 08:49AM	New Strong Sell Stocks for June 15th Zacks
Jun-09-22 05:18AM	New Strong Sell Stocks for June 9th Zacks
Jun-07-22 08:30AM	Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001 GlobeNewswire
Jun-06-22 06:05AM	New Strong Sell Stocks for June 6th Zacks -15.24%
May-16-22 06:55PM	Acer Therapeutics Inc. (ACER) Reports Q1 Loss, Misses Revenue Estimates Zacks +6.19%
04:01PM	Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update GlobeNewswire
May-12-22 08:15AM	OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates Zacks
May-09-22 08:30AM	Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients GlobeNewswire -10.53%
May-06-22 08:30AM	Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference GlobeNewswire
01:40AM	Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference ACCESSWIRE
May-05-22 08:30AM	Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference GlobeNewswire
Apr-12-22 08:30AM	Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting GlobeNewswire
01:20AM	Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting ACCESSWIRE
Apr-11-22 03:48PM	PC sales down 5% in Q1 2022 after two years of growth Yahoo Finance Video -6.18%
Apr-04-22 08:30AM	Acer Therapeutics EDSIVO (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome GlobeNewswire
07:50AM	Midday Stock Movers: Twitter, Tesla, Hertz Rally, DWAC Continues Decline Investing.com
Mar-31-22 08:30AM	Acer Therapeutics Regains Compliance with Nasdaq Listing Standard GlobeNewswire
Mar-30-22 08:30AM	Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause GlobeNewswire
Mar-28-22 07:00AM	SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021 PR Newswire
Mar-07-22 06:15AM	Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities GlobeNewswire
Mar-02-22 05:18PM	Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
Feb-22-22 08:30AM	Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer GlobeNewswire
Feb-08-22 02:44PM	Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised) Zacks
Feb-01-22 08:30AM	Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference GlobeNewswire +7.16%
Jan-27-22 08:30AM	Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences GlobeNewswire
Jan-13-22 09:40AM	Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? Zacks
Jan-07-22 04:29AM	We're Interested To See How Acer Therapeutics (NASDAQ:ACER) Uses Its Cash Hoard To Grow Simply Wall St.
Dec-22-21 08:30AM	Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences GlobeNewswire
Dec-09-21 08:30AM	Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms GlobeNewswire
Nov-22-21 03:43AM	5 Stocks To Watch For November 22, 2021 Benzinga
Nov-19-21 05:00PM	Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update GlobeNewswire
Oct-26-21 08:30AM	Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation GlobeNewswire
Oct-09-21 08:09AM	Acer Therapeutics Inc. (NASDAQ:ACER): Are Analysts Optimistic? Simply Wall St.
Oct-07-21 10:58AM	Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance Zacks -9.31%
08:44AM	FDA Approves NDA for Acer Therapeutics ACER-001; Shares Rise SmarterAnalyst
08:30AM	Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation GlobeNewswire

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schelling Chris	President & CEO	Nov 29	Buy	1.22	819,672	1,000,000	2,712,529	Dec 01 04:02 PM
ASELAGE STEVE	Director	Nov 29	Buy	1.22	409,836	500,000	483,741	Dec 01 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience